All In Biotech

Drug Trial Radar · NCT07606521

A Biosimilar Trial to Investigate PK, PD, Safety With PB018 Versus US-licensed Ocrevus and EU-approved Ocrevus

A Randomized, Parallel-Group Double-Blind, Biosimilar Trial to Compare Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of PB018 Versus Ocrevus® in Participants With Multiple Sclerosis (MS)

Last checked: Nov 20, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 222 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

222

Planned (sponsor's estimate)

Start

Oct 2026

Primary completion

Dec 2027

Study completion Apr 2028

Sponsor

Sponsor type
Industry
First posted
May 26, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, parallel group, double-blind, active-controlled, clinical pharmacology study to compare Pharmacokinetics, Pharmacodynamics and safety of PB018 versus Ocrevus in patients with Multiple Sclerosis.

Conditions

  • Multiple Sclerosis

Interventions

  • US-OcrevusBiological

    Intravenous(IV) infusion

  • PB018Biological

    Intravenous(IV) infusion

  • EU-OcrevusBiological

    Intravenous(IV) infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the concentration time curveTime frame: Week 0 to Week 24

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.